Zoetis Inc. $ZTS Position Increased by Mizuho Markets Americas LLC

Mizuho Markets Americas LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 283.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 522,350 shares of the company’s stock after acquiring an additional 386,100 shares during the period. Zoetis comprises about 1.7% of Mizuho Markets Americas LLC’s investment portfolio, making the stock its 19th biggest holding. Mizuho Markets Americas LLC’s holdings in Zoetis were worth $61,747,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. Prosperity Bancshares Inc bought a new position in shares of Zoetis in the fourth quarter worth $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in Zoetis in the first quarter worth about $28,000. Lodestone Wealth Management LLC acquired a new stake in Zoetis in the fourth quarter worth about $30,000. Root Financial Partners LLC grew its position in Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares in the last quarter. Finally, Elyxium Wealth LLC acquired a new position in Zoetis during the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union, a first-in-class long-acting anti-NGF treatment for cat osteoarthritis pain. The launch supports new international revenue growth and highlights the company’s innovation pipeline. Article title
• Neutral Sentiment: An investor letter highlighted Zoetis as a possible entry point, arguing that temporary concerns may be creating an opportunity. This is supportive sentiment, but it is opinion-based rather than a company-specific catalyst. Article title
• Negative Sentiment: Multiple law firms announced or reminded investors about a securities class action lawsuit against Zoetis, with a July 27 lead-plaintiff deadline. The repeated legal notices may pressure sentiment by keeping alleged investor-harm concerns in focus. Article title

Zoetis Stock Performance

NYSE:ZTS opened at $74.53 on Friday. The company has a 50-day moving average of $77.26 and a 200-day moving average of $104.46. The firm has a market cap of $31.25 billion, a price-to-earnings ratio of 12.36, a price-to-earnings-growth ratio of 1.16 and a beta of 0.75. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a twelve month low of $71.47 and a twelve month high of $160.48.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the previous year, the firm earned $1.48 earnings per share. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts forecast that Zoetis Inc. will post 6.87 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s dividend payout ratio is currently 35.16%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Stifel Nicolaus dropped their price target on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research report on Friday, June 26th. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. UBS Group dropped their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. HSBC cut their target price on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Finally, Barclays lowered their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has an average rating of “Hold” and an average price target of $119.50.

Insider Activity

In related news, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the transaction, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction dated Monday, May 11th. The shares were bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the purchase, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.